Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation

Blood

Volumn 114, Issue 14, 2009, Pages 2888-2899

  Burns, William R ^a   Zheng, Zhili ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; DNA METHYLTRANSFERASE; FLUDARABINE; INTERLEUKIN 2; METHYLTRANSFERASE; PEPTIDE VACCINE; RECOMBINANT VACCINE; RETROVIRUS VECTOR; TRICHOSTATIN A;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER CENTER; CELL FUNCTION; CLINICAL ARTICLE; DNA METHYLATION; DOWN REGULATION; ENZYME INHIBITION; EPIGENETICS; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; LONG TERMINAL REPEAT; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

ADULT; AGED; DNA METHYLATION; FEMALE; GENE SILENCING; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES; TERMINAL REPEAT SEQUENCES; YOUNG ADULT;

EID: 70449486486     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-199216     Document Type: Article

References (50)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
4. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519.
5. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45. (Pubitemid 37328885)
6. Stauss HJ, Cesco-Gaspere M, Thomas S, et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther. 2007;15:1744-1750. (Pubitemid 47434180)
7. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
8. Stewart CL, Stuhlmann H, Jähner D, Jaenisch R. De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells. Proc Natl Acad Sci U S A. 1982;79:4098-4102. (Pubitemid 12035085)
9. Jähner D, Stuhlmann H, Stewart CL, et al. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature. 1982;298:623-628.
10. Krall WJ, Skelton DC, Yu XJ, et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 1996;3:37-48.
11. Krall W, Kohn DB. Expression levels by retroviral vectors based upon the N2 and the MFG backbones. Gene Ther. 1996;3:365.
12. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138. (Pubitemid 124000640)
13. Swindle CS, Klug CA. Mechanisms that regulate silencing of gene expression from retroviral vectors [review]. J Hematother Stem Cell Res. 2002;11:449-456.
14. Ellis J, Yao S. Retrovirus silencing and vector design: relevance to normal and cancer stem cells [review]? Curr Gene Ther. 2005;5:367-373. (Pubitemid 41052428)
15. Pannell D, Osborne CS, Yao S, et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J. 2000;19:5884-5894. (Pubitemid 30828344)
16. Lorincz MC, Schubeler D, Groudine M. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol Cell Biol. 2001;21:7913-7922. (Pubitemid 33051784)
17. Yao S, Sukonnik T, Kean T, Bharadwaj RR, Pasceri P, Ellis J. Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. Mol Ther. 2004;10:27-36. (Pubitemid 38878146)
18. Swindle CS, Kim HG, Klug CA. Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells. J Biol Chem. 2004;279:34-41.
19. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472.
20. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201.
21. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-3295.
22. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758. (Pubitemid 28110836)
23. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother. 2003;26:349-356.
24. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003;9:2973-2980.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
27. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J Biol Chem. 2000;275:6353-6359. (Pubitemid 30129929)
28. Young JI, Smith JR. DNA methyltransferase inhibition in normal human fibroblasts induces a p21-dependent cell cycle withdrawal. J Biol Chem. 2001;276:19610-19616. (Pubitemid 37411301)
29. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270:475-480.
30. Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum Gene Ther. 1996;7:1123-1129. (Pubitemid 26202730)
31. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270:470-475.
32. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8:423-425. (Pubitemid 34546725)
33. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466-1476. (Pubitemid 46871329)
34. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10:5-18. (Pubitemid 38878144)
35. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood. 2007;109:4698-4707. (Pubitemid 46827761)
36. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A. 1998;95:1201-1206. (Pubitemid 28124936)
37. Morgan RA, Walker R, Carter CS, et al. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther. 2005;16:1065-1074. (Pubitemid 41324566)
38. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-16015
39. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24:e20-2.
40. Lamers CH, Gratama JW, Pouw NM, et al. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum Gene Ther. 2005;16:1452-1462.
41. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177:6548-6559. (Pubitemid 44628874)
42. Wang L, Robbins PB, Carbonaro DA, Kohn DB. High-resolution analysis of cytosine methylation in 5′ long terminal repeat of retroviral vectors. Hum Gene Ther. 1998;9:2321-2330. (Pubitemid 28523981)
43. Pollok KE, Hanenberg H, Noblitt TW, et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol. 1998;72:4882-4892. (Pubitemid 28215666)
44. Pollok KE, van der Loo JC, Cooper RJ, Kennedy L, Williams DA. Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum Gene Ther. 1999;10:2221-2236. (Pubitemid 29416301)
45. Quinn ER, Lum LG, Trevor KT. T cell activation modulates retrovirus-mediated gene expression. Hum Gene Ther. 1998;9:1457-1467. (Pubitemid 28379085)
46. + T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. Blood. 1997;89:1987-1995.
47. + T cells. Hum Gene Ther. 2004;15:648-658.
48. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003;4:1169-1176.
49. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454-465. (Pubitemid 46834848)
50. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.